Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a research study using caffeine in children who have an obstructive sleep apnea (OSA). OSA means children who stop breathing during their sleep due to obstruction in their airway. The purpose of this study is to determine whether caffeine when given in the vein, will wake children up faster and decrease post-anesthesia airway obstruction, as well as the safety and if the drug agrees with the child compared to a placebo (an inactive or dummy agent).
Patients with OSA are reported to have a higher rate of severe respiratory complications associated with upper airway obstruction during anesthesia and sedation or immediately after anesthesia. Children with OSA (especially those under three years of age, those with severe OSA, cerebral palsy or craniofacial anomalies) are at increased risks for post-operative complications, and require careful monitoring post-operatively.
Although the etiology of obstructive sleep apnea is mainly obstruction due to anatomical and neuromuscular abnormalities, we believe that a central element may contribute to OSA.
The aim of this study is to evaluate whether administration of caffeine to children with OSA, scheduled for elective T & A under general anesthesia contributes to a faster recovery, less post-operative complications, and a shorter stay in the PACU, DSU and the hospital.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator | Saline |
|
| Caffeine | Active Comparator | Caffeine benzoate |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Caffeine | Drug | Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo. | The number of children having adverse post-extubation respiratory events, including laryngospasm, upper airway obstruction, apnea, desaturation (defined as decrease in oxygen saturation <95% while breathing oxygen via mask for any length of time) and need for reintubation, both in the Operating Room and in the PACU was recorded. | Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room. |
| Measure | Description | Time Frame |
|---|---|---|
| Occurence of Post Extubatory Respiratory Adverse Events. | The overall occurance of adverse post-extubation respiratory events, including laryngospasm, upper airway obstruction, apnea, desaturation (defined as decrease in oxygen saturation <95% while breathing oxygen via mask for any length of time) and need for reintubation, both in the OR and in the PACU was noted. | Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Samia N. Khalil, MD | The University of Texas Health Science Center, Houston | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Texas, Health Science Center at Houston, Children's Memorial Hermann Hospital | Houston | Texas | 77030 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | Normal Saline |
| FG001 | Caffeine | Caffeine benzoate |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Children in group two will receive an amount of normal saline equal to Caffeine |
|
|
| Extubation Time. | Time from end of anesthesia until extubation. | Duration from anesthesia end until extubation time. |
| Awakening Time | A child with a Steward Recovery Scale score of 6 is defined as awake, coughing/crying, and has purposeful movements. | Awakening time from end of anesthesia until the child reached a score of 6 on the Steward recovery score. |
| Post Anesthesia Care Unit (PACU) Duration | Time spent in PACU following surgical procedure prior to discharge home or hospital admission. |
| Hospital Discharge Time | Children were discharged from the hospital when they reached the hospital discharge criteria: they were awake, had stable vital signs, were breathing adequately, had O2 saturation >95% while breathing room air, were able to swallow fluids, had no or minimal pain, and were able to ambulate without excessive nausea, vomiting, or dizziness. | Total time from end anesthesia to discharge home |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | Normal Saline |
| BG001 | Caffeine | Caffeine benzoate |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Children Who Developed Postextubation Adverse Respiratory Events Compared to Placebo. | The number of children having adverse post-extubation respiratory events, including laryngospasm, upper airway obstruction, apnea, desaturation (defined as decrease in oxygen saturation <95% while breathing oxygen via mask for any length of time) and need for reintubation, both in the Operating Room and in the PACU was recorded. | The analysis was per protocol. | Posted | Number | Participants | Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room. |
|
|
| |||||||||||||||||||||||||||||
| Secondary | Occurence of Post Extubatory Respiratory Adverse Events. | The overall occurance of adverse post-extubation respiratory events, including laryngospasm, upper airway obstruction, apnea, desaturation (defined as decrease in oxygen saturation <95% while breathing oxygen via mask for any length of time) and need for reintubation, both in the OR and in the PACU was noted. | Per protocol | Posted | Number | Participants | Time post extubation in OR and PACU until the patient was discharged from the PACU to go home or to a hospital room. |
|
| ||||||||||||||||||||||||||||||
| Secondary | Extubation Time. | Time from end of anesthesia until extubation. | Posted | Mean | Standard Deviation | minutes | Duration from anesthesia end until extubation time. |
|
| ||||||||||||||||||||||||||||||
| Secondary | Awakening Time | A child with a Steward Recovery Scale score of 6 is defined as awake, coughing/crying, and has purposeful movements. | Posted | Mean | Standard Deviation | Minutes | Awakening time from end of anesthesia until the child reached a score of 6 on the Steward recovery score. |
|
| ||||||||||||||||||||||||||||||
| Secondary | Post Anesthesia Care Unit (PACU) Duration | Posted | Mean | Standard Deviation | minutes | Time spent in PACU following surgical procedure prior to discharge home or hospital admission. |
|
| |||||||||||||||||||||||||||||||
| Secondary | Hospital Discharge Time | Children were discharged from the hospital when they reached the hospital discharge criteria: they were awake, had stable vital signs, were breathing adequately, had O2 saturation >95% while breathing room air, were able to swallow fluids, had no or minimal pain, and were able to ambulate without excessive nausea, vomiting, or dizziness. | Posted | Mean | Standard Deviation | Minutes | Total time from end anesthesia to discharge home |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | Normal Saline | 0 | 36 | 0 | 36 | ||
| EG001 | Caffeine | Caffeine benzoate | 0 | 36 | 0 | 36 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Samia Khalil, M.D./ Professor | University of Texas Medical School/ Houston | 713-500-6242 | Samia.N.Khalil@uth.tmc.edu |
| ID | Term |
|---|---|
| D020181 | Sleep Apnea, Obstructive |
| D011183 | Postoperative Complications |
| ID | Term |
|---|---|
| D012891 | Sleep Apnea Syndromes |
| D001049 | Apnea |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D002110 | Caffeine |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D014970 | Xanthines |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D011688 | Purinones |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |
Not provided
Not provided
| >=65 years |
|
| Male |
|
|
|
|
|
|